CKIP-1 inhibits cardiac hypertrophy by regulating class ii histone deacetylase phosphorylation through recruiting PP2A

Circulation

Volumn 126, Issue 25, 2012, Pages 3028-3040

  Zhang, Lingqiang ^b,c   Ling, Shukuan ^a   Sun, Qiao ^a   Li, Yuheng ^a   Zhang, Luo ^b   Zhang, Pengfei ^a   Wang, Xiaogang ^a   Tian, Chunyan ^b   Li, Qi ^a   Song, Jinping ^a   Liu, Hongju ^a   Kan, Guanghan ^a   Cao, Hongqing ^a   Huang, Zengming ^a   Nie, Jielin ^a   Bai, Yanqiang ^a   Chen, Shanguang ^a   Li, Yinghui ^a   He, Fuchu ^b   Li, Yingxian ^a  

^a China Astronaut Research and Training Center   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

cardiomyopathy; heart failure; hypertrophy; molecular biology

Indexed keywords

CASEIN KINASE 2 INTERACTING PROTEIN 1; HISTONE DEACETYLASE 4; MYOCYTE ENHANCER FACTOR 2; MYOCYTE SPECIFIC ENHANCER FACTOR 2C; PHOSPHOPROTEIN PHOSPHATASE 2A; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

AGED; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ECHOCARDIOGRAPHY; ENZYME ACTIVE SITE; ENZYME BINDING; ENZYME PHOSPHORYLATION; GENE EXPRESSION; GENE OVEREXPRESSION; GENETIC TRANSCRIPTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE OVERLOAD; HISTOLOGY; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOPRECIPITATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

AGE FACTORS; ANIMALS; CARDIOMEGALY; CARRIER PROTEINS; HISTONE DEACETYLASES; MALE; MICE; MICE, KNOCKOUT; MYOCARDIUM; MYOGENIC REGULATORY FACTORS; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; TRANSCRIPTION, GENETIC;

EID: 84871334776     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.112.102780     Document Type: Article

References (47)

1. Shah AM, Mann DL. In search of new therapeutic targets and strategies for heart failure: Recent advances in basic science. Lancet. 2011;378: 704-712.
2. Drazner MH. The progression of hypertensive heart disease. Circulation. 2011;123:327-334.
3. Bossuyt J, Helmstadter K, Wu X, Clements-Jewery H, Haworth RS, Avkiran M, Martin JL, Pogwizd SM, Bers DM. Ca2+/calmodulin-dependent protein kinase IIdelta and protein kinase D overexpression reinforce the histone deacetylase 5 redistribution in heart failure. Circ Res. 2008;102:695-702.
4. Backs J, Olson EN. Control of cardiac growth by histone acetylation/deacetylation. Circ Res. 2006;98:15-24.
5. McKinsey TA, Zhang CL, Lu J, Olson EN. Signal-dependent nuclear export of a histone deacetylase regulates muscle differentiation. Nature. 2000;408:106-111.
6. Chawla S, Vanhoutte P, Arnold FJ, Huang CL, Bading H. Neuronal activity-dependent nucleocytoplasmic shuttling of HDAC4 and HDAC5. J Neurochem. 2003;85:151-159.
7. Kao HY, Verdel A, Tsai CC, Simon C, Juguilon H, Khochbin S. Mechanism for nucleocytoplasmic shuttling of histone deacetylase 7. J Biol Chem. 2001;276:47496-47507.
8. Vega RB, Harrison BC, Meadows E, Roberts CR, Papst PJ, Olson EN, McKinsey TA. Protein kinases c and d mediate agonist-dependent cardiac hypertrophy through nuclear export of histone deacetylase 5. Mol Cell Biol. 2004;24:8374-8385.
9. Backs J, Song K, Bezprozvannaya S, Chang S, Olson EN. CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy. J Clin Invest. 2006;116:1853-1864.
10. Grozinger CM, Schreiber SL. Regulation of histone deacetylase 4 and 5 and transcriptional activity by 14-3-3-dependent cellular localization. Proc Natl Acad Sci USA. 2000;97:7835-7840.
11. Paroni G, Cernotta N, Dello Russo C, Gallinari P, Pallaoro M, Foti C, Talamo F, Orsatti L, Steinkuhler C, Brancolini C. PP2A regulates HDAC4 nuclear import. Mol Biol Cell. 2008;19:655-667.
12. Kozhemyakina E, Cohen T, Yao TP, Lassar AB. Parathyroid hormone-related peptide represses chondrocyte hypertrophy through a protein phosphatase 2A/histone deacetylase 4/MEF2 pathway. Mol Cell Biol. 2009;29:5751-5762.
13. Bosc DG, Graham KC, Saulnier RB, Zhang C, Prober D, Gietz RD, Litchfield DW. Identification and characterization of CKIP-1, a novel pleckstrin homology domain-containing protein that interacts with protein kinase CK2. J Biol Chem. 2000;275:14295-14306.
14. Safi A, Vandromme M, Caussanel S, Valdacci L, Baas D, Vidal M, Brun G, Schaeffer L, Goillot E. Role for the pleckstrin homology domain-containing protein CKIP-1 in phosphatidylinositol 3-kinase-regulated muscle differentiation. Mol Cell Biol. 2004;24:1245-1255.
15. Canton DA, Olsten ME, Kim K, Doherty-Kirby A, Lajoie G, Cooper JA, Litchfield DW. The pleckstrin homology domain-containing protein CKIP-1 is involved in regulation of cell morphology and the actin cyto-skeleton and interaction with actin capping protein. Mol Cell Biol. 2005; 25:3519-3534.
16. Zhang L, Xing G, Tie Y, Tang Y, Tian C, Li L, Sun L, Wei H, Zhu Y, He F. Role for the pleckstrin homology domain-containing protein CKIP-1 in AP-1 regulation and apoptosis. EMBO J. 2005;24:766-778.
17. Canton DA, Olsten ME, Niederstrasser H, Cooper JA, Litchfield DW. The role of CKIP-1 in cell morphology depends on its interaction with actin-capping protein. J Biol Chem. 2006;281:36347-36359.
18. Zhang L, Tie Y, Tian C, Xing G, Song Y, Zhu Y, Sun Z, He F. CKIP-1 recruits nuclear ATM partially to the plasma membrane through interaction with ATM. Cell Signal. 2006;18:1386-1395.
19. Zhang L, Tang Y, Tie Y, Tian C, Wang J, Dong Y, Sun Z, He F. The PH domain containing protein CKIP-1 binds to IFP35 and Nmi and is involved in cytokine signaling. Cell Signal. 2007;19:932-944.
20. Xi S, Tie Y, Lu K, Zhang M, Yin X, Chen J, Xing G, Tian C, Zheng X, He F, Zhang L. N-terminal PH domain and C-terminal auto-inhibitory region of CKIP-1 coordinate to determine its nucleus-plasma membrane shuttling. FEBS Lett. 2010;584:1223-1230.
21. Tokuda E, Fujita N, Oh-hara T, Sato S, Kurata A, Katayama R, Itoh T, Takenawa T, Miyazono K, Tsuruo T. Casein kinase 2-interacting protein-1, a novel Akt pleckstrin homology domain-interacting protein, down-regulates PI3K/Akt signaling and suppresses tumor growth in vivo. Cancer Res. 2007;67:9666-9676.
22. Lu K, Yin X, Weng T, Xi S, Li L, Xing G, Cheng X, Yang X, Zhang L, He F. Targeting WW domains linker of HECT-type ubiquitin ligase Smurf1 for activation by CKIP-1. Nat Cell Biol. 2008;10:994-1002.
23. Ago T, Liu T, Zhai P, Chen W, Li H, Molkentin JD, Vatner SF, Sadoshima J. A redox-dependent pathway for regulating class II HDACs and cardiac hypertrophy. Cell. 2008;133:978-993.
24. Little GH, Bai Y, Williams T, Poizat C. Nuclear calcium/calmodulin- dependent protein kinase IIdelta preferentially transmits signals to histone deacetylase 4 in cardiac cells. J Biol Chem. 2007;282:7219-7231.
25. Yang XJ, Gregoire S. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol Cell Biol. 2005;25: 2873-2884.
26. McKinsey TA, Zhang CL, Olson EN. MEF2: a calcium-dependent regulator of cell division, differentiation and death. Trends Biochem Sci. 2002;27:40-47.
27. Chang S, Bezprozvannaya S, Li S, Olson EN. An expression screen reveals modulators of class II histone deacetylase phosphorylation. Proc Natl Acad Sci USA. 2005;102:8120-8125.
28. McKinsey TA, Kuwahara K, Bezprozvannaya S, Olson EN. Class II histone deacetylases confer signal responsiveness to the ankyrin-repeat proteins ANKRA2 and RFXANK. Mol Biol Cell. 2006;17:438-447.
29. Berdeaux R, Goebel N, Banaszynski L, Takemori H, Wandless T, Shelton GD, Montminy M. SIK1 is a class II HDAC kinase that promotes survival of skeletal myocytes. Nat Med. 2007;13:597-603.
30. Dequiedt F, Martin M, Von Blume J, Vertommen D, Lecomte E, Mari N, Heinen MF, Bachmann M, Twizere JC, Huang MC, Rider MH, Piwnica-Worms H, Seufferlein T, Kettmann R. New role for hPar-1 kinases EMK and C-TAK1 in regulating localization and activity of class IIa histone deacetylases. Mol Cell Biol. 2006;26:7086-7102.
31. Wang AH, Kruhlak MJ, Wu J, Bertos NR, Vezmar M, Posner BI, Bazett-Jones DP, Yang XJ. Regulation of histone deacetylase 4 by binding of 14-3-3 proteins. Mol Cell Biol. 2000;20:6904-6912.
32. Yang XJ, Seto E. The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and men. Nat Rev Mol Cell Biol. 2008;9: 206-218.
33. Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet. 2003;19:286-293.
34. Shima H, Tohda H, Aonuma S, Nakayasu M, DePaoli-Roach AA, Sugimura T, Nagao M. Characterization of the PP2A alpha gene mutation in okadaic acid-resistant variants of CHO-K1 cells. Proc Natl Acad Sci USA. 1994;91:9267-9271.
35. Vega RB, Matsuda K, Oh J, Barbosa AC, Yang X, Meadows E, McAnally J, Pomajzl C, Shelton JM, Richardson JA, Karsenty G, Olson EN. Histone deacetylase 4 controls chondrocyte hypertrophy during skel-etogenesis. Cell. 2004;119:555-566.
36. Miano JM, Berk BC. HDAC7 supports vascular integrity. Nat Med. 2006;12:997-998.
37. Moresi V, Williams AH, Meadows E, Flynn JM, Potthoff MJ, McAnally J, Shelton JM, Backs J, Klein WH, Richardson JA, Bassel-Duby R, Olson EN. Myogenin and class II HDACs control neurogenic muscle atrophy by inducing E3 ubiquitin ligases. Cell. 2010;143:35-45.
38. Chang S, Young BD, Li S, Qi X, Richardson JA, Olson EN. Histone deacetylase 7 maintains vascular integrity by repressing matrix metallo-proteinase 10. Cell. 2006;126:321-334.
39. Chang S, McKinsey TA, Zhang CL, Richardson JA, Hill JA, Olson EN. Histone deacetylases 5 and 9 govern responsiveness of the heart to a subset of stress signals and play redundant roles in heart development. Mol Cell Biol. 2004;24:8467-8476.
40. Passier R, Zeng H, Frey N, Naya FJ, Nicol RL, McKinsey TA, Overbeek P, Richardson JA, Grant SR, Olson EN. Cam kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo. J Clin Invest. 2000;105:1395-1406.
41. Lu J, McKinsey TA, Nicol RL, Olson EN. Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases. Proc Natl Acad Sci USA. 2000;97:4070-4075.
42. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009;10:32-42.
43. Berger SL. The complex language of chromatin regulation during transcription. Nature. 2007;447:407-412.
44. Illi B, Dello Russo C, Colussi C, Rosati J, Pallaoro M, Spallotta F, Rotili D, Valente S, Ragone G, Martelli F, Biglioli P, Steinkuhler C, Gallinari P, Mai A, Capogrossi MC, Gaetano C. Nitric oxide modulates chromatin folding in human endothelial cells via protein phosphatase 2A activation and class II histone deacetylases nuclear shuttling. Circ Res. 2008;102: 51-58.
45. Martin M, Potente M, Janssens V, Vertommen D, Twizere JC, Rider MH, Goris J, Dimmeler S, Kettmann R, Dequiedt F. Protein phosphatase 2A controls the activity of histone deacetylase 7 during T cell apoptosis and angiogenesis. Proc Natl Acad Sci USA. 2008;105:4727-4732.
46. Hardt SE, Sadoshima J. Negative regulators of cardiac hypertrophy. Cardiovasc Res. 2004;63:500-509.
47. Finckenberg P, Mervaala E. Novel regulators and drug targets of cardiac hypertrophy. J Hypertens. 2010;28(suppl 1):S33-S38.